CP
VRTX icon

Cornerstone Planning’s Vertex Pharmaceuticals VRTX Stock Holding History

Cornerstone Planning’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Hold
450
– – 0.05% 135
2026
Q1 		$201K Hold
450
– – 0.05% 141
2025
Q4 		$204K Buy
+450
New +$194K 0.05% 131

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Cornerstone Planning's VRTX Position: Q2 2026 in Review

Cornerstone Planning held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 450 shares worth $224K. The position accounts for 0.05% of the portfolio, ranked #135.

Cornerstone Planning first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,743 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Cornerstone Planning held 450 shares of Vertex Pharmaceuticals worth $224K as of Q2 2026.
  • Cornerstone Planning left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.05% of Cornerstone Planning's portfolio in Q2 2026, its #135 holding.
  • Cornerstone Planning first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1,743 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Cornerstone Planning's 13F filing for Q2 2026, filed 30 Jul 2026.